The stomach and/or upper duodenum contain sites of action that control meal size and intermeal interval length by exogenous rat gastrin releasing peptide

Washington, Martha C.; Aglan, Amnah H.; Sayegh, Ayman I.

doi:10.1016/j.peptides.2014.02.004

Cited by 17 publications

(20 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One catheter was implanted in each rat, as described previously (Sayegh, et al, 2014; Washington, et al, 2014). Catheters (Micro-Renathane R-ITC-SP 9.5, Braintree Scientific, Braintree MA) were 24 cm long.…”

Section: Methodsmentioning

confidence: 99%

“…In addition to the better anatomical specificity, this technique permits the use of smaller doses of GLP-1 than necessary in intraperitoneal-injection tests, which may minimizes possible side effects. We previously used this intra-arterial catheterization technique to test CA and CMA infusions of cholecystokinin (CCK) and gastrin releasing peptide (GRP) (Sayegh, et al, 2015; Washington, Aglan, & Sayegh, 2014). …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Exogenous glucagon-like peptide-1 acts in sites supplied by the cranial mesenteric artery to reduce meal size and prolong the intermeal interval in rats

et al. 2016

Self Cite

View full text Add to dashboard Cite

Three experiments were done to better assess the gastrointestinal (GI) site(s) of action of GLP-1 on food intake in rats. First, near-spontaneous nocturnal chow meal size (MS), intermeal intervals (IMI) length and satiety ratios (SR = MS/IMI) were measured after infusion of saline, 0.025 or 0.5 nmol/kg GLP-1 into the celiac artery (CA, supplying the stomach and upper duodenum), cranial mesenteric artery (CMA, supplying small and all of the large intestine except the rectum), femoral artery (FA, control) or portal vein (PV, control). Second, infusion of 0.5 nmol/kg GLP-1 was tested after pretreatment with the GLP-1 receptor (GLP-1R) antagonist exendin-4(3–39) via the same routes. Third, the regional distribution of GLP-1R in the rat GI tract was determined using rtPCR. CA, CMA and FA GLP-1 reduced first MS relative to saline, with the CMA route more effective than the others. Only CMA GLP-1 prolonged the IMI. None of the infusions affected second MS or later eating. CA and CMA GLP-1 increased the SR, with the CMA route more effective than the CA route. CMA exendin-4 (3–39) infusion reduced the effect of CMA GLP-1. Finally GLP-1R expression was found throughout the GI tract. The results suggest that exogenous GLP-1 acts in multiple GI sites to reduce feeding under our conditions and that GLP-1R in the area supplied by the CMA, i.e., the small and part of the large intestine, plays the leading role.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Exogenous glucagon-like peptide-1 acts in sites supplied by the cranial mesenteric artery to reduce meal size and prolong the intermeal interval in rats

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…One catheter was implanted in each rat, and the meal patterns (meal was consumption of ≥ 0.2 g, and intermeal interval [IMI] was no feeding activity for ≥ 15 min), were done as described in details previously (Sayegh et al, 2015; Washington et al, 2014a; Washington et al, 2015; Williams et al, 2016). …”

Section: Methodsmentioning

confidence: 99%

“…Furthermore, the site of action controlling MS and IMI length by exogenous GRP has also been examined (Washington et al, 2014a). We have shown that the vascular bed of the celiac artery (CA, supplying the stomach and the upper duodenum) contains sites of action controlling MS and IMI length by exogenous GRP-29 but not GRP-10.…”

Section: Introductionmentioning

confidence: 99%

“…Based on our previous work (Washington et al, 2014a) the current study measured MS (normal rat chow), IMI length, latency to first meal, duration of first meal, total number of meals and total food intake during a 24 hour period by GRP-10 and GRP-29 (0.5 nmol/kg, the highest effective dose) infused in the CA and the cranial mesenteric artery (CMA, supplying small and part of the large intestine) in near spontaneously free feeding rats pretreated with the specific BB 2 receptor antagonist BW2258U89 (, 0.1 mg/kg (Kirkham et al, 1994)) in the same arteries prior to the onset of the dark cycle. The BW2258U89 receptor antagonist is a specific GRP, BB 2 , receptor antagonist which belongs to a class of bombesin receptor antagonists (modified GRP(15-27) peptides, with D-Pro26 and D-Ala24 moieties).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The BB2 receptor antagonist BW2258U89 attenuates the feeding responses evoked by exogenous gastrin releasing peptide-29

Washington

Mhalhal

Sayegh

2016

Hormones and Behavior

Self Cite

View full text Add to dashboard Cite

This confirmatory work is aimed to test that the hypothesis that the gastrin releasing peptide (GRP) receptor – the BB2 receptor – is necessary for reduction of meal size (MS) and prolongation of the intermeal interval (IMI) by the small and the large forms of GRP in the rat, GRP-10 and GRP-29, and to confirm the sites of action regulating such responses – the vascular bed of the celiac artery (CA, supplying stomach and upper duodenum). To pursue these aims we measured first MS and IMI length in response to GRP-10 and GRP-29 (0, 0.5 nmol/kg) infused in the CA (n=8 rats) and the cranial mesenteric artery (CMA, supplying the small and part of the large intestine, n=8 rats) in near spontaneously free feeding rats pretreated with the BB2 receptor antagonist BW2258U89 (0.1 mg/kg) in the same arteries prior to the onset of the dark cycle. We found that GRP-29, but not GRP-10, infused by the CA reduced MS and prolonged the IMI by decreasing meal latency and meal duration and the BB2 receptor antagonist BW2258U89 infused in the same artery attenuated these responses. These results suggest that the BB2 receptor is necessary for reduction of MS and prolongation of the IMI by exogenous GRP-29, and the vascular bed of the CA, stomach and upper duodenum, contains sites of action regulating these feeding responses.

show abstract

Peptide Tyrosine Tyrosine 3-36 Reduces Meal Size and Activates the Enteric Neurons in Male Sprague–Dawley Rats

et al. 2017

View full text Add to dashboard Cite

show abstract

The stomach and/or upper duodenum contain sites of action that control meal size and intermeal interval length by exogenous rat gastrin releasing peptide

Cited by 17 publications

References 13 publications

Exogenous glucagon-like peptide-1 acts in sites supplied by the cranial mesenteric artery to reduce meal size and prolong the intermeal interval in rats

Exogenous glucagon-like peptide-1 acts in sites supplied by the cranial mesenteric artery to reduce meal size and prolong the intermeal interval in rats

The BB2 receptor antagonist BW2258U89 attenuates the feeding responses evoked by exogenous gastrin releasing peptide-29

Peptide Tyrosine Tyrosine 3-36 Reduces Meal Size and Activates the Enteric Neurons in Male Sprague–Dawley Rats

Contact Info

Product

Resources

About